Elevance Health (ELV) Announces Fiscal Q3 2025 Results

Elevance Health, Inc. (NYSE:ELV) is one of the best long term low volatility stocks to buy right now. Elevance Health, Inc. (NYSE:ELV) reported its fiscal Q3 2025 results on October 21, announcing $50.1 billion in operating revenue for the quarter, up 12.0% compared to the same quarter last year. Diluted EPS for the quarter reached $5.32, while adjusted diluted EPS was $6.03.

The company reaffirmed its fiscal year 2025 benefit expense ratio and adjusted diluted EPS guidance of around 90.0% and around $30.00, respectively. Elevance Health, Inc. (NYSE:ELV) also returned $3.3 billion of capital to shareholders year-to-date.

Management further reported that the operating cash flow for fiscal Q3 2025 was $4.2 billion year-to-date, or “0.8 times GAAP net income, a decrease of $0.9 billion year over year reflecting in part the Provider Settlement Agreement payment for the multi-district BCBSA litigation”. Cash and investments at the parent company come up to around $2.6 billion as of September 30, 2025.

Elevance Health, Inc. (NYSE:ELV) is a health company that operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a range of health plans and services, while the CarelonRx segment manages pharmacy services. The Carelon Services segment offers various healthcare-related services by integrating behavioral, physical, pharmacy, and social services.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.